138 related articles for article (PubMed ID: 9174853)
1. Cyclic and individualized administration of gonadotropin-releasing hormone agonists plus progestogens: an alternative protocol for contraception.
Chryssikopoulos A; Phocas I; Rizos D; Kontoravdis A
Gynecol Endocrinol; 1997 Apr; 11(2):119-26. PubMed ID: 9174853
[TBL] [Abstract][Full Text] [Related]
2. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
3. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
4. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
5. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
8. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
9. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
10. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
11. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
13. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
14. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
Letterie GS
Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
[TBL] [Abstract][Full Text] [Related]
16. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
18. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
[TBL] [Abstract][Full Text] [Related]
19. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
